Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c

NCT06803771 is registered in ClinicalTrials.gov with University Hospital Southampton NHS Foundation Trust as lead sponsor.

NCT NCT06803771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06803771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Phase
Not applicable
Overall status
Recruiting
Start date
May 21, 2025
Completion date
July 31, 2032
Enrollment
5,000 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, pancreatic cancer, adult